Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson’s disease dementia
Nagaendran Kandiah,1,2 Ming-Chyi Pai,3,4 Vorapun Senanarong,5 Irene Looi,6,7 Encarnita Ampil,8 Kyung Won Park,9 Ananda Krishna Karanam,10 Stephen Christopher11 1Department of Neurology, National Neuroscience Institute, Tan Tock Seng Hospital, 2Duke-NUS, Graduate Medical School, Singapore; 3Division...
Guardado en:
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2017
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/740898df6938411badbc5c6c821ebf0b |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:740898df6938411badbc5c6c821ebf0b |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:740898df6938411badbc5c6c821ebf0b2021-12-02T00:48:23ZRivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson’s disease dementia1178-1998https://doaj.org/article/740898df6938411badbc5c6c821ebf0b2017-04-01T00:00:00Zhttps://www.dovepress.com/rivastigmine-the-advantages-of-dual-inhibition-of-acetylcholinesterase-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Nagaendran Kandiah,1,2 Ming-Chyi Pai,3,4 Vorapun Senanarong,5 Irene Looi,6,7 Encarnita Ampil,8 Kyung Won Park,9 Ananda Krishna Karanam,10 Stephen Christopher11 1Department of Neurology, National Neuroscience Institute, Tan Tock Seng Hospital, 2Duke-NUS, Graduate Medical School, Singapore; 3Division of Behavioral Neurology, Department of Neurology, 4Alzheimer’s Disease Research Center, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan City, Taiwan; 5Division of Neurology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand; 6Clinical Research Centre, 7Department of Medicine, Hospital Seberang Jaya, Penang, Malaysia; 8Department of Neurology and Psychiatry, Faculty of Medicine and Surgery, University of Santo Tomas, Manila, Philippines; 9Department of Neurology and Cognitive Disorders and Dementia Center, Institute of Convergence Bio-Health, Dong-A University College of Medicine, Busan, Republic of Korea; 10Novartis Healthcare Private Limited, Hyderabad, India; 11Novartis (Singapore) Pte. Ltd., Singapore Abstract: Several studies have demonstrated clinical benefits of sustained cholinesterase inhibition with rivastigmine in Alzheimer’s disease (AD) and Parkinson’s disease dementia (PDD). Unlike donepezil and galantamine that selectively inhibit acetylcholinesterase (AChE; EC 3.1.1.7), rivastigmine is a unique cholinesterase inhibitor with both AChE and butyrylcholinesterase (BuChE; EC 3.1.1.8) inhibitory activity. Rivastigmine is also available as transdermal patch that has been approved by the US Food and Drug Administration for the treatment of mild, moderate, and severe AD as well as mild-to-moderate PDD. In this review, we explore the role of BuChE inhibition in addition to AChE inhibition with rivastigmine in the outcomes of cognition, global function, behavioral symptoms, and activities of daily living. Additionally, we review the evidence supporting the use of dual AChE-BuChE inhibitory activity of rivastigmine as a therapeutic strategy in the treatment of neurological disorders, with a focus on the role of rivastigmine in subcortical dementias such as vascular dementia (VaD) and PDD. Toward this objective, we performed a literature search in PubMed and Ovid with limits to articles published in the English language before June 2016. The available evidence from the literature suggests that the dual inhibition of AChE and BuChE may afford additional therapeutic potential of rivastigmine in subcortical dementias (subcortical VaD and PDD) with benefits on cognition and behavioral symptoms. Rivastigmine was found to specifically benefit executive dysfunction frequently observed in subcortical dementias; however, large randomized clinical studies are warranted to support these observations. Keywords: acetylcholinesterase, BuChE genotype, butyrylcholinesterase, Parkinson’s disease dementia, rivastigmine, subcortical vascular dementiaKandiah NPai MCSenanarong VLooi IAmpil EPark KWKaranam AKChristopher SDove Medical PressarticleacetylcholinesteraseBuChE genotypebutyrylcholinesteraseParkinson's disease dementiarivastigminesubcortical vascular dementiaGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 12, Pp 697-707 (2017) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
acetylcholinesterase BuChE genotype butyrylcholinesterase Parkinson's disease dementia rivastigmine subcortical vascular dementia Geriatrics RC952-954.6 |
| spellingShingle |
acetylcholinesterase BuChE genotype butyrylcholinesterase Parkinson's disease dementia rivastigmine subcortical vascular dementia Geriatrics RC952-954.6 Kandiah N Pai MC Senanarong V Looi I Ampil E Park KW Karanam AK Christopher S Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson’s disease dementia |
| description |
Nagaendran Kandiah,1,2 Ming-Chyi Pai,3,4 Vorapun Senanarong,5 Irene Looi,6,7 Encarnita Ampil,8 Kyung Won Park,9 Ananda Krishna Karanam,10 Stephen Christopher11 1Department of Neurology, National Neuroscience Institute, Tan Tock Seng Hospital, 2Duke-NUS, Graduate Medical School, Singapore; 3Division of Behavioral Neurology, Department of Neurology, 4Alzheimer’s Disease Research Center, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan City, Taiwan; 5Division of Neurology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand; 6Clinical Research Centre, 7Department of Medicine, Hospital Seberang Jaya, Penang, Malaysia; 8Department of Neurology and Psychiatry, Faculty of Medicine and Surgery, University of Santo Tomas, Manila, Philippines; 9Department of Neurology and Cognitive Disorders and Dementia Center, Institute of Convergence Bio-Health, Dong-A University College of Medicine, Busan, Republic of Korea; 10Novartis Healthcare Private Limited, Hyderabad, India; 11Novartis (Singapore) Pte. Ltd., Singapore Abstract: Several studies have demonstrated clinical benefits of sustained cholinesterase inhibition with rivastigmine in Alzheimer’s disease (AD) and Parkinson’s disease dementia (PDD). Unlike donepezil and galantamine that selectively inhibit acetylcholinesterase (AChE; EC 3.1.1.7), rivastigmine is a unique cholinesterase inhibitor with both AChE and butyrylcholinesterase (BuChE; EC 3.1.1.8) inhibitory activity. Rivastigmine is also available as transdermal patch that has been approved by the US Food and Drug Administration for the treatment of mild, moderate, and severe AD as well as mild-to-moderate PDD. In this review, we explore the role of BuChE inhibition in addition to AChE inhibition with rivastigmine in the outcomes of cognition, global function, behavioral symptoms, and activities of daily living. Additionally, we review the evidence supporting the use of dual AChE-BuChE inhibitory activity of rivastigmine as a therapeutic strategy in the treatment of neurological disorders, with a focus on the role of rivastigmine in subcortical dementias such as vascular dementia (VaD) and PDD. Toward this objective, we performed a literature search in PubMed and Ovid with limits to articles published in the English language before June 2016. The available evidence from the literature suggests that the dual inhibition of AChE and BuChE may afford additional therapeutic potential of rivastigmine in subcortical dementias (subcortical VaD and PDD) with benefits on cognition and behavioral symptoms. Rivastigmine was found to specifically benefit executive dysfunction frequently observed in subcortical dementias; however, large randomized clinical studies are warranted to support these observations. Keywords: acetylcholinesterase, BuChE genotype, butyrylcholinesterase, Parkinson’s disease dementia, rivastigmine, subcortical vascular dementia |
| format |
article |
| author |
Kandiah N Pai MC Senanarong V Looi I Ampil E Park KW Karanam AK Christopher S |
| author_facet |
Kandiah N Pai MC Senanarong V Looi I Ampil E Park KW Karanam AK Christopher S |
| author_sort |
Kandiah N |
| title |
Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson’s disease dementia |
| title_short |
Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson’s disease dementia |
| title_full |
Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson’s disease dementia |
| title_fullStr |
Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson’s disease dementia |
| title_full_unstemmed |
Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson’s disease dementia |
| title_sort |
rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and parkinson’s disease dementia |
| publisher |
Dove Medical Press |
| publishDate |
2017 |
| url |
https://doaj.org/article/740898df6938411badbc5c6c821ebf0b |
| work_keys_str_mv |
AT kandiahn rivastigminetheadvantagesofdualinhibitionofacetylcholinesteraseandbutyrylcholinesteraseanditsroleinsubcorticalvasculardementiaandparkinsonrsquosdiseasedementia AT paimc rivastigminetheadvantagesofdualinhibitionofacetylcholinesteraseandbutyrylcholinesteraseanditsroleinsubcorticalvasculardementiaandparkinsonrsquosdiseasedementia AT senanarongv rivastigminetheadvantagesofdualinhibitionofacetylcholinesteraseandbutyrylcholinesteraseanditsroleinsubcorticalvasculardementiaandparkinsonrsquosdiseasedementia AT looii rivastigminetheadvantagesofdualinhibitionofacetylcholinesteraseandbutyrylcholinesteraseanditsroleinsubcorticalvasculardementiaandparkinsonrsquosdiseasedementia AT ampile rivastigminetheadvantagesofdualinhibitionofacetylcholinesteraseandbutyrylcholinesteraseanditsroleinsubcorticalvasculardementiaandparkinsonrsquosdiseasedementia AT parkkw rivastigminetheadvantagesofdualinhibitionofacetylcholinesteraseandbutyrylcholinesteraseanditsroleinsubcorticalvasculardementiaandparkinsonrsquosdiseasedementia AT karanamak rivastigminetheadvantagesofdualinhibitionofacetylcholinesteraseandbutyrylcholinesteraseanditsroleinsubcorticalvasculardementiaandparkinsonrsquosdiseasedementia AT christophers rivastigminetheadvantagesofdualinhibitionofacetylcholinesteraseandbutyrylcholinesteraseanditsroleinsubcorticalvasculardementiaandparkinsonrsquosdiseasedementia |
| _version_ |
1718403446367846400 |